Breast cancer, with the incidence of 2% annually (
1), is one of the most common malignancies among Iranian women (
2) and the lowest mean age in the middle east (
3). Although its treatments such as surgery, radiotherapy, chemotherapy and hormonal therapy reduce mortality rates of breast cancer, each may lead to different side effects (
4).
The secondary upper limb lymph edema related to breast cancer (
5) is one of the most common morbidities and important consequences of treatment (
6) that is usually unilateral (
5), with mild to severe intensity at any time during the life (
7). It is known as a chronic, incurable (
6) visible and progressive disease (
8). So it is causing physical and psychological disorders (
9). Without intervention, lymph edema can lead to progressive swollen and larger in size of limb or localized fluid accumulation in other body areas, tightness, heaviness, limitation of mobility in upper limb and hand, numbness and tingling, pain, fatigue (
5), skin changes (
10), deformities (
11), body image impairment, stress, depression, loss of confidence, lack of participation in social activities (9), and even death in advanced stages of lymph edema in these patients (
12).
Despite the large studies for the treatment of lymphedema, there is not any certain cure (
8). The gold standard treatment so far has been complex decongestive therapy (CDT). The international association of north America (LANA) has known CDT as common, standard, and an effective treatment. It is a two-phase program. The first phase (intensive phase) usually, depending on the degree of edema, lasts 2 to 4 weeks. The patient receives treatment 5 days per week and the second phase (maintenance phase) immediately begins after the first phase that is life-long self-care to maintain the size of the limb (
5-
8).